Company Overview and News

 
SBI to sell 8 bad loans to recover dues worth over ₹3,900 crore

2018-09-18 livemint
New Delhi: State Bank of India, the country’s largest lender, will sell eight non-performing assets to recover dues worth over ₹3,900 crore and has invited bids from asset reconstruction companies (ARCs) and financial institutions (FIs).
BRFL 500102 BALLARPUR 532614 532976 JAIBALAJI IMPEXFERRO 532678 SBAZ

 
SBI to sell 8 NPAs to recover dues worth over Rs 3,900 cr

2018-09-18 moneycontrol
The country's largest lender State Bank of India will sell eight non-performing assets to recover dues worth over Rs 3,900 crore and has invited bids from asset reconstruction companies (ARCs) and financial institutions (FIs).
BRFL 500102 BALLARPUR 532614 532976 JAIBALAJI IMPEXFERRO 532678 SBAZ

1
SBI does a U-turn on stressed assets sale, seeks deals with ARCs

2018-09-17 livemint
Mumbai: State Bank of India has made a complete U-turn on stressed assets undergoing insolvency proceedings. Instead of initiating bankruptcy proceedings against the defaulting companies, the state-owned lender is now looking to sell them to asset reconstruction companies (ARCs), two senior bank officials said, requesting anonymity.
532388 IOB HDB 500180 500102 HDFCBANK BALLARPUR 532614 532976 JAIBALAJI IMPEXFERRO SBAZ

 
Is spotting good debt funds a Herculean task?

2018-09-14 thehindubusinessline
KS Badri Narayanan Those who think investing in debt funds are risk-free, be cautious. Recently, rating downgrades of debt instruments of Infrastructure Leasing & Financial Services and its subsidiary IL&FS Financial Services had sent at least 25 mutual fund schemes that had exposure to IL&FS group companies, into a tizzy.
AMKD 500102 AMTEKAUTO BALLARPUR 520077

 
Which mutual funds have how much exposure to ILamp;FS and what are MFs saying?

2018-09-14 moneycontrol
Credit rating downgrades of debt instruments of Infrastructure Leasing & Financial Services and its subsidiary IL&FS Financial Services had adverse impact on the net asset value of at least 25 mutual fund schemes, that had exposure to IL&FS group companies as of Aug 31.
AMKD 500102 AMTEKAUTO BALLARPUR 520077

 
Investors jittery over ₹2,800-crore mutual fund investments in IL&FS

2018-09-12 thehindubusinessline
Suresh P Iyengar/Surabhi Notwithstanding the runaway success of the ‘Mutual funds sahi hai’ campaign, most investors in debt schemes of top mutual funds are a worried lot due to the mark-down in their investments.
AMKD 500102 AMTEKAUTO BALLARPUR 520077

 
Telangana Government announces subsidies for revival of BILT unit

2018-09-05 moneycontrol
The Telangana government announced several measures, including subsidies and waiver of commercial taxes dues, aimed at revival of a pulp unit of Ballarpur Industries Limited (BILT) in the state, shut since 2014.
500102 BALLARPUR

 
Ballarpur Industries Limited - Updates

2018-09-05 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
500102 BALLARPUR

 
Ballarpur Industries Limited - Updates

2018-08-31 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
500102 BALLARPUR

 
Ballarpur Industries Limited - AGM/Book Closure

2018-08-30 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
500102 BALLARPUR

 
AION Cap targets $1 billion corpus for new fund

2018-08-27 livemint
Mumbai: Special situations investor AION Capital Ltd is raising its second India-focussed fund with a targeted corpus of over $1 billion, said two people with direct knowledge of the matter, requesting anonymity.
500093 CPGVY 500228 500102 CGVA BALLARPUR CROMPGREAV JSWSTEEL CGVD CPGZF

 
Oriental Bank invites i-bankers to sell shares acquired through SDR

2018-08-02 thehindubusinessline
In a bid to liquidate equity shares allotted to it under restructuring package, Oriental Bank of Commerce is planning to rope in an advisor to assess its equity stake in 30 to 40 listed as well as unlisted companies acquired under the package and advise it on company-wise feasibility of stake sale.
500102 BALLARPUR 532775 GTLINFRA

 
Ballarpur Industries Limited - Outcome of Board Meeting

2018-08-01 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
500102 BALLARPUR

 
Tata Global, RInfra, Jindal Saw results

2018-07-31 thehindubusinessline
AB Fashion, Apollo Tyres, Astec Lifesciences, Ballarpur Industries, Exide India, Elecon Engineering, Emami, FDC, Gateway Distriparks, HFCL, HEG, Indoco Remedies, Jayshree Tea, Jindal Saw, Navneet Education, Orient Paper, Pidilite Industries, Poly Medicure, RInfra, Repro India, Tata Global, Thangamayil, Torrent Power, TCI Developers, V2 Retail, Zuari Agro, and Zuari Global are among the 51 firms that will declare their April-June quarter results on Wednesday.
533393 REPRO NAVNETEDUL 531768 532779 TCIDEVELOP 532612 532215 PIDILITIND ZUARIGLOB PDLTY AXISBANK TORNTPOWER 500378 505700 500331 ELECON V2RETAIL AXB KMBKY 500877 INDOCO APOLLOTYRE 532867 ASTEC AYRQY 532622 532687 AXBKY 533138 AXBA ONP 508989 GDL JINDALSAW KOTAKBANK 500102 500247 BALLARPUR 500780 POLYMED

 
ITC aims to match revenues from managed hotels to that from owned properties

2018-07-27 livemint
Kolkata: After years of pursuing growth by building properties across India, ITC Ltd is looking to raise the share of revenue from managed hotels in a bid to shore up shareholder returns from the segment.
500102 BALLARPUR

Related Articles

DMPI: DelMar Pharmaceuticals Analysis and Research Report

7h - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...